Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32685139 | 0.89 | CYP4F2 (0.46) | CYP4F2CYP4A11TDP1APPMEN1 | |
| SCHEMBL9344845 | 0.86 | CYP4F2 (0.50) | CYP4F2CYP4A11TDP1APPMEN1 | |
| SCHEMBL9344841 | 0.86 | CYP4F2 (0.50) | CYP4F2CYP4A11TDP1APPMEN1 | |
| SCHEMBL23545820 | 0.85 | CYP4F2 (0.49) | CYP4F2CYP4A11TDP1ALDH1A1TSHR | |
| SCHEMBL23545821 | 0.85 | CYP4F2 (0.49) | CYP4F2CYP4A11TDP1ALDH1A1TSHR | |
| SCHEMBL3185725 | 0.85 | TDP1 (0.68) | TDP1APPKMT2AALDH1A1TSHR | |
| SCHEMBL17107198 | 0.82 | TDP1 (0.68) | CYP4F2CYP4A11TDP1APPMEN1 | |
| SCHEMBL19795505 | 0.81 | CYP4F2 (0.45) | CYP4F2CYP4A11TDP1ALDH1A1HDAC8 | |
| SCHEMBL304455 | 0.81 | CYP4F2 (0.74) | CYP4F2CYP4A11TDP1APPKMT2A | |
| SCHEMBL25392344 | 0.79 | CYP4F2 (0.53) | CYP4F2CYP4A11TDP1APPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397968-B1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2017116994-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | CYP4F2 2236/4885CYP4A11 3745/4885TDP1 4743/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | CYP4F2 2236/4885CYP4A11 3745/4885TDP1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.